Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intraperitoneal gemcitabine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
Gemcitabine is a nucleoside analog chemotherapy agent being investigated by MedStar Health Research Institute for the treatment of resectable pancreatic and periampullary adenocarcinoma. In this specific clinical protocol (MedStar Georgetown IRB Protocol 2009-455), the drug is administered via an intraperitoneal route rather than the standard intravenous route. The treatment regimen involves hyperthermic intraperitoneal chemotherapy (HIPEC) administered intraoperatively during a Whipple procedure, followed by six months of adjuvant normothermic intraperitoneal chemotherapy (NIPEC). Gemcitabine acts as a pyrimidine antimetabolite that inhibits ribonucleotide reductase and competes with deoxycytidine triphosphate for incorporation into DNA, leading to chain termination and apoptosis. This regional delivery approach is designed to maximize local drug concentration and reduce peritoneal recurrence.
- Brand names
- Gemzar
- Other names
- Intraperitoneal GemcitabineIP GemcitabineHeated Intraoperative Intraperitoneal GemcitabineNormothermic Intraperitoneal Gemcitabine
02
Targets
RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on intraperitoneal gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intraperitoneal gemcitabine.